Researchers Report Engineered Extracellular Vesicles Restore Macrophage Metabolism to Accelerate Aged Wound Repair

A preclinical study shows that engineered extracellular vesicles can accelerate aged skin repair in mice by upregulating ASS1, thereby reversing macrophage senescence and restoring mitochondrial energy metabolism.

A study published in Advanced Materials reports the development of 4-octyl itaconate-engineered extracellular vesicles (4OI-EVs) designed to address immunosenescence in aged wound healing.

The researchers identified a metabolic disorder involving the arginine-oxidative phosphorylation axis in aging skin, which contributes to macrophage dysfunction and chronic wound persistence.

Treatment with 4OI-EVs, which naturally possess an abundance of mitochondrial proteins, reduced cellular senescence and restored metabolic function in senescent macrophages.

The therapy resulted in decreased glycolysis and increased arginine-oxidative phosphorylation via elevated levels of argininosuccinate synthetase 1 (ASS1), reversing mitochondrial dysfunction and mitophagy suppression.

Targeting immunosenescence through metabolic intervention represents an alternative approach to traditional senolytic strategies, focusing on restoring the function of senescent immune cells rather than clearing them.

Identifying the ASS1 pathway as a critical regulator of mitophagy and mitochondrial quality control in macrophages provides a novel therapeutic node for addressing localized tissue aging and chronic diabetic wounds.

The study highlights the utility of engineered extracellular vesicles as targeted delivery vehicles capable of transferring active mitochondrial proteins directly to dysfunctional tissue.

The findings provide preclinical validation for therapeutic approaches focusing on mitophagy and mitochondrial quality control to treat age-related tissue degradation.

The success of the EV-based delivery model may increase research and development interest in extracellular vesicle therapeutics for localized indications such as wound care and dermatology.

Further translation of 4OI-EVs into larger animal models of impaired wound healing to establish safety profiles and dosing requirements.

Academic and clinical exploration of whether small-molecule therapeutics targeting the ASS1 pathway can replicate the mitophagy-restoring benefits observed in this EV study.